Finanzas de STAAR Surgical Co (STAA)STAASTAAR Surgical Co

STAAR Surgical Company (STAA) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is ICLs, accounting for 97.4% of total sales, equivalent to $41.50M. Another important revenue stream is Other surgical products. Understanding this composition is critical for investors evaluating how STAA navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, STAAR Surgical Company maintains a gross margin of 74.55%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 10.80%, while the net margin is 8.61%. These profitability ratios, combined with a Return on Equity (ROE) of 1.09%, provide a clear picture of how effectively STAA converts its operational activities into shareholder value.

In the context of the broader market, STAA competes directly with industry leaders such as AORT and IART. With a market capitalization of $1.09B, it holds a leading position in the sector. When comparing efficiency, STAA's gross margin of 74.55% stands against AORT's 64.03% and IART's 56.00%. Such benchmarking helps identify whether STAAR Surgical Company is trading at a premium or discount relative to its financial performance.

The company's gross margin has been strong, peaking at 82.21% in Q3 2025, while recent net income has shown improvement, with $8.06 million in Q2 2026, indicating a recovery trend.